•
NRNP 6630 MIDTERM EXAM (2 VERSIONS, 200 Q & A)
VERIFIED QUESTIONS AND ANSWERS
DOWNLOAD TO SECURE HIGH SCORE IN
EXAM
COMPLETE AND BEST DOCUMENT FOR
EXAM PREPARATION
ALREADY GRADED A+
, NRNP 6630 Midterm Exam
Question 1
I I
When an unstable patient asks why it is necessary to add medications to his
I I I I I I I I I I I I I
current regimen, the PMHNP’s best response would be:
I I I I I I I I
Selected C. I
I
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter systems in
I I I I I I I I
the Ibrain. IOften, Ia Isingle Imedication Imay Ionly Ieffect Ione Ior Itwo Iof Ithe Idys-functioning
I
systems. IThe Iaddition Iof Ianother Imedication Ican Iwork Iwith Ithe Icurrent Imedication Iin
I
symptoms.”
stabilizing Imultiple Ineurotransmitter Isystems Iand Ihelp Ito Ialleviate Iyour I
I
• Question 2 I
The PMHNP is meeting with a new mother who would like to begin taking
I I I I I I I I I I I I I
medication again to treat her bipolar depression; she is breastfeeding her 2-
I I I I I I I I I I I I
month old daughter. The PMHNP recognizes that which of the following
I I II I I I I I I I
medications is contraindicated for this patient? I I I I I I
Selected Answer: C.
I I
Lithium (Lithobid) I
• Question 3 I
1 out of 1 points
I I I I
Mr. Gordon is a middle-aged client who was started on antidepressant
I I I I I I I I I I
monotherapy for depression. After beginning this medication, the PMHNP
I I I II I I I I I
, A
I noticed that this client seemed to swing into a hypomanic episode. What can
I I I I I I I I I I I I
I the PMHNP infer from this behavior change?
I I I I I I
Selected Answer: A. I I
This client may have Bipolar III disorder
I I I I I I
• Question 4 I
1 out of 1 points
I I I I
A patient presents with frequent episodes of mania. Which statement describes
I I I I I I I I I I
an appropriate treatment approach for this patient?
I I I I I I I
Selected Answer: B. I I
“The patient could benefit from an anticonvulsant.”
I I I I I I II
• Question 5 I
1 out of 1 points
I I I I
The student inquires about antipsychotic medications. Which response by the
I I I I I I I I I
PMHNP describes the factors that contribute to reduced risk of extrapyramidal
I I I I I I I I I I I
symptoms (EPS) for patients who take antipsychotics?
I I I I I I I
Selected B. I
Answer:
I Those that are potent D2 antagonists with 5HT2A antagonism
I I I I I I I I
properties
I
• Question 6 I
1 out of 1 points I I I I
After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for
I I I I I I I I I I I
Iwhich possible effect? I I
Selected Answer: D. I I
All of the aboveI I I
, • Question 7 I
1 out of 1 points
I I I I
The PMHNP is caring for a patient who is taking antipsychotics heard the
I I I I I I I I I I I I
psychiatrist tell the patient that the patient would be placed on a different
I I I I I I I I I I I I I
antipsychotic agent called an atypical antipsychotic. What neurotransmitters
I I I I I I I I
will this new medication work on?
I I I I I I
Selected Answer: A. I I
dopamine and serotonin I I
• Question 8 I
1 out of 1 points
I I I I
While genes have potential to modify behavior, behavior can also modify genes.
I I I I I I I I I I I
How do genes impact this process?
I I I I I I
Selected Answer: B. I I
Changes made to proteins lead to changes in behavior.
I I I I I I I I
• Question 9 I
1 out of 1 points
I I I I
Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
I I I I I I I I I
established history of depression. When meeting with the PMHNP, she
I I I I I I I I I I
presents with apathy and withdrawn social behavior, and she reports a loss
of
I I I I I I I I I I I I I
I joy from enjoyable activities since starting her new medication. What does the
I I I I I I I I I I I
I PMHNP infer from this encounter with the client?
I I I I I I I
Selected C. I
IAnswer: The new medication is blocking D2 receptors in the mesolimbic
I I I I I I I I I
Isystem
• Question 10 I
1 out of 1 points
I I I I
Inursing student is seeking clarification on the use of anticonvulsants to treat
I I I I I I I I I I I
NRNP 6630 MIDTERM EXAM (2 VERSIONS, 200 Q & A)
VERIFIED QUESTIONS AND ANSWERS
DOWNLOAD TO SECURE HIGH SCORE IN
EXAM
COMPLETE AND BEST DOCUMENT FOR
EXAM PREPARATION
ALREADY GRADED A+
, NRNP 6630 Midterm Exam
Question 1
I I
When an unstable patient asks why it is necessary to add medications to his
I I I I I I I I I I I I I
current regimen, the PMHNP’s best response would be:
I I I I I I I I
Selected C. I
I
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter systems in
I I I I I I I I
the Ibrain. IOften, Ia Isingle Imedication Imay Ionly Ieffect Ione Ior Itwo Iof Ithe Idys-functioning
I
systems. IThe Iaddition Iof Ianother Imedication Ican Iwork Iwith Ithe Icurrent Imedication Iin
I
symptoms.”
stabilizing Imultiple Ineurotransmitter Isystems Iand Ihelp Ito Ialleviate Iyour I
I
• Question 2 I
The PMHNP is meeting with a new mother who would like to begin taking
I I I I I I I I I I I I I
medication again to treat her bipolar depression; she is breastfeeding her 2-
I I I I I I I I I I I I
month old daughter. The PMHNP recognizes that which of the following
I I II I I I I I I I
medications is contraindicated for this patient? I I I I I I
Selected Answer: C.
I I
Lithium (Lithobid) I
• Question 3 I
1 out of 1 points
I I I I
Mr. Gordon is a middle-aged client who was started on antidepressant
I I I I I I I I I I
monotherapy for depression. After beginning this medication, the PMHNP
I I I II I I I I I
, A
I noticed that this client seemed to swing into a hypomanic episode. What can
I I I I I I I I I I I I
I the PMHNP infer from this behavior change?
I I I I I I
Selected Answer: A. I I
This client may have Bipolar III disorder
I I I I I I
• Question 4 I
1 out of 1 points
I I I I
A patient presents with frequent episodes of mania. Which statement describes
I I I I I I I I I I
an appropriate treatment approach for this patient?
I I I I I I I
Selected Answer: B. I I
“The patient could benefit from an anticonvulsant.”
I I I I I I II
• Question 5 I
1 out of 1 points
I I I I
The student inquires about antipsychotic medications. Which response by the
I I I I I I I I I
PMHNP describes the factors that contribute to reduced risk of extrapyramidal
I I I I I I I I I I I
symptoms (EPS) for patients who take antipsychotics?
I I I I I I I
Selected B. I
Answer:
I Those that are potent D2 antagonists with 5HT2A antagonism
I I I I I I I I
properties
I
• Question 6 I
1 out of 1 points I I I I
After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for
I I I I I I I I I I I
Iwhich possible effect? I I
Selected Answer: D. I I
All of the aboveI I I
, • Question 7 I
1 out of 1 points
I I I I
The PMHNP is caring for a patient who is taking antipsychotics heard the
I I I I I I I I I I I I
psychiatrist tell the patient that the patient would be placed on a different
I I I I I I I I I I I I I
antipsychotic agent called an atypical antipsychotic. What neurotransmitters
I I I I I I I I
will this new medication work on?
I I I I I I
Selected Answer: A. I I
dopamine and serotonin I I
• Question 8 I
1 out of 1 points
I I I I
While genes have potential to modify behavior, behavior can also modify genes.
I I I I I I I I I I I
How do genes impact this process?
I I I I I I
Selected Answer: B. I I
Changes made to proteins lead to changes in behavior.
I I I I I I I I
• Question 9 I
1 out of 1 points
I I I I
Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
I I I I I I I I I
established history of depression. When meeting with the PMHNP, she
I I I I I I I I I I
presents with apathy and withdrawn social behavior, and she reports a loss
of
I I I I I I I I I I I I I
I joy from enjoyable activities since starting her new medication. What does the
I I I I I I I I I I I
I PMHNP infer from this encounter with the client?
I I I I I I I
Selected C. I
IAnswer: The new medication is blocking D2 receptors in the mesolimbic
I I I I I I I I I
Isystem
• Question 10 I
1 out of 1 points
I I I I
Inursing student is seeking clarification on the use of anticonvulsants to treat
I I I I I I I I I I I
